Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 16/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.42 |
| ▸ | QPCT | Q16769 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7241642 | 0.84 | PDE4A (0.50) | PDE4APDE4BPDE4DPDE4CQPCT | |
| SCHEMBL28139968 | 0.81 | QPCT (0.46) | PDE4APDE4BPDE4DPDE4CQPCT | |
| SCHEMBL6418032 | 0.74 | PDE4A (0.45) | PDE4APDE4BPDE4DPDE4C | |
| SCHEMBL7379692 | 0.74 | PDE4A (0.41) | PDE4APDE4BPDE4DPDE4CQPCT | |
| SCHEMBL3624661 | 0.70 | PDE4B (0.49) | PDE4APDE4BPDE4DPDE4C | |
| SCHEMBL7381565 | 0.70 | PDE4A (0.51) | PDE4APDE4BPDE4DPDE4C | |
| SCHEMBL1918433 | 0.70 | PDE4A (0.53) | PDE4APDE4BPDE4DPDE4C | |
| SCHEMBL30074724 | 0.70 | PDE4A (0.53) | PDE4APDE4BPDE4DPDE4C | |
| SCHEMBL6155940 | 0.70 | PDE4A (0.53) | PDE4APDE4BPDE4DPDE4C | |
| SCHEMBL6155742 | 0.70 | PDE4A (0.53) | PDE4APDE4BPDE4DPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050112069-A1 | Pharmaceutical composition of a pde4 or pde 3/4 inhibitor and histamine receptor antagonist | NYCOMED GMBH (DE) | 2005-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050112069-A1 | Pharmaceutical composition of a pde4 or pde 3/4 inhibitor and histamine receptor antagonist | HRH4, PDE4A, PDE4B | PDE4A 2/4885PDE4B 3/4885PDE4D 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.